Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Two-Year Assessment of Bimekizumab's Efficacy, Safety, and Treatment Retention in Chronic Plaque Psoriasis: Insights from Northern Italy's Real-World Data

  • By

  • Zeno Fratton

  • Stefano Bighetti

  • Luca Bettolini

  • Marina Venturini

  • Mariateresa Rossi

  • Andrea Carugno

  • Nicola Zerbinati

  • Giuseppe Stinco

  • Enzo Errichetti

  • June 28, 2026

Share

Original Source(s)

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy

  • by Zeno Fratton, Stefano Bighetti, Luca Bettolini, Marina Venturini, Mariateresa Rossi, Andrea Carugno, Nicola Zerbinati, Giuseppe Stinco, Enzo Errichetti

  • June 28, 2026

Related Content

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

Divergent immunometabolic reprogramming in psoriasis and atopic dermatitis: a tale of two inflammatory skin diseases